Antares Pharma Stock News

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

Antares Pharma (NASDAQ:ATRS) is scheduled to announce Q4 results on Thursday, Mar. 3, before market open.Consensus EPS estimate is $0.01 and consensus revenue estimate is $47.19M

EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42 nd Annual Healthcare Conference being held on March 7-9, 2022.

EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Ex

During the last session, Antares Pharma Inc. (NASDAQ:ATRS)s traded shares were 0.46 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stocks price was $3.49, reflecting an intraday loss of -2.51% or -$0.09. The 52-week high for the ATRS share is $5.07, that puts it down Antares Pharma Inc. (NASDAQ: ATRS) Is Up 4.18% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-

The FDA has accepted a New Drug Application for the oral testosterone replacement therapy Tlando from Antares Pharma.

Antares is a company I've followed for years, and I recently decided to reinitiate a position. That's because the stock price has fallen significantly with the broader market while management has made

The FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The

Antares Pharma''s (ATRS) hydrocortisone rescue pen ATRS-1902 received the U.S

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue.  The development program for ATRS-1902 supports a proposed indication of

Antares Pharma Inc (NASDAQ: ATRS ) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary